

Lialda - (1.2 gm; Tablet, Delayed Release)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Mesalamine | Innovator | Shire |
| Dosage | 1.2 gm; Tablet, Delayed Release | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.